Register Login

Krystal Biotech (KRYS)

  • Event
  • May 20, 2022, 12:26 UTC

(99% Neutral) KRYSTAL BIOTECH, INC. (KRYS) Announces Enrollment Update for tropism Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:30 p.m.

    📋 KRYSTAL BIOTECH, INC. (KRYS) - Clinical Trial Update

    Filing Date: 2022-05-20

    Accepted: 2022-05-20 08:26:23

    Event Type: Clinical Trial Update

    Event Details:

    Krystal Biotech (KRYS) Announces Clinical Trial Update Krystal Biotech (KRYS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: tropism, allows
    • Diseases/Conditions: episomal delivery
    • Clinical Stage: Phase 3, NCT04491604
    • Collaboration: the Society for Investigative Dermatology

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Krystal Biotech
    • CIK: 0001711279
    • Ticker Symbol: KRYS
    • Period End Date: 2022-05-20
    • Document Type: 8-K

Search

News categories